Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • c-Myc tag Peptide: Precision Reagent for Immunoassays and...

    2026-01-15

    c-Myc tag Peptide: Precision Reagent for Immunoassays and Cancer Biology

    Principle & Setup: Harnessing the Power of the Synthetic c-Myc Peptide

    The c-Myc tag Peptide (SKU: A6003) from APExBIO is a synthetic, sequence-defined peptide corresponding to amino acids 410–419 of the human c-Myc protein. This 10-residue myc tag sequence (EQKLISEEDL) is engineered to serve as a competitive inhibitor for anti-c-Myc antibody binding. Used primarily in immunoassays, such as immunoprecipitation (IP), immunoblotting (Western), and immunofluorescence, the c-Myc Peptide displaces c-Myc-tagged fusion proteins from antibody complexes, offering a reliable negative control or a means to elute specifically bound proteins.

    Beyond its utility in standard workflows, the synthetic c-Myc peptide for immunoassays is pivotal in dissecting protein–protein interactions, validating antibody specificity, and exploring the broader mechanisms of transcription factor regulation. Given c-Myc’s central role as a proto-oncogene in cancer research—modulating cell proliferation, apoptosis, and gene amplification—it is essential to deploy tools with high mechanistic precision. The A6003 peptide is soluble up to ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (with ultrasonic treatment), ensuring compatibility across diverse assay platforms.

    Step-by-Step Workflow: Enhancing Immunoassay Specificity and Efficiency

    1. Preparing the Peptide Solution

    • Remove the peptide vial from -20°C storage and equilibrate to room temperature before opening to avoid condensation.
    • For optimal solubility, dissolve the peptide in DMSO at concentrations up to 60.17 mg/mL. Alternatively, use water with ultrasonic agitation to reach up to 15.7 mg/mL. Do not use ethanol, as the peptide is insoluble in this solvent.
    • Aliquot the solution to minimize freeze-thaw cycles. Store aliquots at -20°C, desiccated, and avoid long-term storage in solution to preserve peptide integrity.

    2. Displacement of c-Myc-Tagged Fusion Proteins in Immunoassays

    • After binding your c-Myc-tagged protein to an anti-c-Myc antibody (immobilized on beads or membrane), wash to remove nonspecific interactors.
    • Add the synthetic c-Myc peptide at a final concentration typically ranging from 100–500 µg/mL, depending on assay sensitivity and antibody affinity.
    • Incubate under optimized conditions (e.g., 30 min at 4°C for immunoprecipitation) to promote competitive displacement.
    • Collect the peptide-eluted fraction, which contains the c-Myc-tagged protein, now released from the antibody complex.
    • For negative controls, process parallel samples without the peptide or with an irrelevant peptide of similar length and charge.

    3. Anti-c-Myc Antibody Binding Inhibition

    • To validate antibody specificity, pre-incubate the anti-c-Myc antibody with an excess of the c-Myc tag peptide before probing blots or cells. A signal decrease confirms specific recognition of the myc tag sequence.

    4. Integration With Advanced Assays

    • Combine with chromatin immunoprecipitation (ChIP) assays to dissect c-Myc mediated gene amplification and transcriptional regulation in cancer models.
    • Utilize in high-throughput screening platforms for identifying modulators of transcription factor activity, as highlighted in emerging autophagy research (Wu et al., 2021).

    Advanced Applications and Comparative Advantages

    The c-Myc tag Peptide’s robust performance extends well beyond routine immunoassays, positioning it as a critical research reagent for cancer biology and mechanistic studies of transcription factor regulation. Recent translational studies have leveraged the peptide to:

    • Dissect Cell Proliferation and Apoptosis Regulation: By enabling precise elution and inhibition assays, researchers can probe the downstream consequences of c-Myc activation, such as upregulation of cyclins or downregulation of apoptosis regulators.
      For example, the peptide has been instrumental in studies exploring how proto-oncogene c-Myc contributes to malignant progression via gene amplification and cell cycle control.
    • Illuminate Crosstalk With Autophagic Pathways: The interplay between transcription factors like c-Myc and IRF3 in immune signaling and selective autophagy is a frontier area. As demonstrated by Wu et al. (2021), transcription factor stability and activation are tightly regulated by post-translational modifications and degradation pathways. Synthetic tag peptides provide a precise tool to isolate these factors and study their fate under selective autophagy or immune challenge.
    • Benchmarking Against Other Epitope Tags: Compared to other peptide tags, such as FLAG or HA, the myc tag sequence offers a unique balance of compact size and high-affinity antibody recognition, reducing steric hindrance and improving assay sensitivity.

    For deeper insights and comparative analysis, the article "Redefining Transcription Factor Modulation" extends these findings by positioning A6003 in the context of autophagy-driven transcription factor control and preclinical cancer models. Meanwhile, "c-Myc tag Peptide: Next-Generation Probe for Transcription Factor Analysis" complements this view by focusing on mechanistic specificity and its impact on synthetic immunoassays. Both resources underscore the peptide’s value in bridging molecular discoveries with translational impact.

    Troubleshooting and Optimization Tips

    • Peptide Solubility: If solubility is suboptimal in water, apply brief ultrasonic treatment or switch to DMSO. Always avoid ethanol, which leads to precipitation and loss of peptide activity.
    • Peptide Stability: Minimize time in solution at room temperature. Prepare fresh aliquots and keep desiccated at -20°C. Avoid repeated freeze-thaw cycles.
    • Assay Sensitivity: If displacement of c-Myc-tagged fusion proteins is inefficient, increase the peptide concentration in stepwise increments (from 100 to 500 µg/mL). Confirm that the antibody is functionally active and that incubation times are sufficient for competitive binding.
    • Antibody Specificity: Always include negative controls (no peptide or irrelevant peptide) to distinguish specific anti-c-Myc antibody binding inhibition from nonspecific background.
    • Detection Issues: In Western blot or immunoprecipitation, ensure that the displacement step is performed at cold temperatures (4°C) to prevent protein degradation. Use protease inhibitors as required.
    • Batch Consistency: APExBIO's rigorous manufacturing and QC ensure reproducibility; nonetheless, confirm lot-to-lot consistency with small-scale pilot assays before scaling up.

    For additional troubleshooting scenarios and advanced optimization strategies, the article "c-Myc tag Peptide (A6003): Unraveling Its Role in Precision Immunoassays" provides an in-depth discussion on assay design, specificity validation, and integration with contemporary autophagy research.

    Future Outlook: Expanding the Role of c-Myc Peptide in Research Innovation

    As the understanding of transcription factor dynamics and proto-oncogene regulation deepens, the c-Myc tag Peptide is poised to play an even greater role in advanced research workflows. Future applications are likely to include:

    • Integration with High-Content Screening: Quantitative data from high-throughput immunoassays utilizing synthetic c-Myc peptide for immunoassays can accelerate drug discovery targeting oncogenic c-Myc pathways.
    • Live-Cell Imaging and Proteomics: Incorporation of the peptide into live-cell displacement assays and mass spectrometry workflows will further elucidate the interactome and degradation routes of c-Myc and related transcription factors.
    • Personalized Oncology: With the rise of precision medicine, the ability to modulate and study c-Myc mediated gene amplification and cell fate decisions will inform targeted therapies for cancers characterized by dysregulated c-Myc activity.
    • Mechanistic Dissection of Immune Pathways: Building on work such as Wu et al. (2021), the peptide will support studies investigating the balance between interferon production, immune suppression, and autophagic degradation of transcription factors.

    The APExBIO c-Myc tag Peptide stands as a benchmark tool for reproducibility and specificity in cancer biology, immunology, and systems biology. As synthetic tag technology advances, researchers will continue to benefit from its robust performance, flexible solubility, and precise sequence definition.

    References